(ARWR) Arrowhead Pharmaceuticals - Ratings and Ratios

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biopharmaceutical company focused on developing RNA interference (RNAi) therapies for severe and rare diseases. Its pipeline includes multiple candidates in advanced clinical stages, addressing lipid metabolism disorders, liver diseases, and pulmonary conditions. Plozasiran has completed Phase 3 trials for hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome. Olpasiran is in Phase 3 to reduce apolipoprotein A production, while Fazirsiran is in Phase 3 for liver disease linked to alpha-1 antitrypsin deficiency. Earlier-stage candidates include Zodasiran (Phase 2b) for dyslipidemia, GSK-4532990 for metabolic-dysfunction steatohepatitis, and Daplusiran/Tomligisiran (Phase 2) for chronic hepatitis B. The company also has several Phase 1/2a programs, such as ARO-MMP7 for idiopathic pulmonary fibrosis, ARO-CFB for complement-mediated kidney disease, and ARO-ATXN2 for Spinocerebellar Ataxia Type 2. Arrowhead collaborates with major pharmaceutical firms, including GlaxoSmithKline, Horizon Therapeutics, Takeda, and Amgen. Founded in 2003, the company is based in Pasadena, California.

Ticker Symbol: ARWR Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Biotechnology

Average Volume 20d: 1791921 Last Price: 13.89 SMA 20: 12.15 SMA 50: 14.73 SMA 200: 19.95 ATR: 1.00

Market Cap: 1658.79M USD P/E: None P/E Forward: 111.11 P/B: 29.35 P/S: 663.52 RoE: None

3-Month Forecast: Based on technical and fundamental analysis, ARWR is expected to face downward pressure due to its current price (13.89) trading below its SMA 20 (12.15) and SMA 50 (14.73), while significantly below SMA 200 (19.95). The ATR of 1.00 suggests moderate volatility. On the fundamental side, the high P/B ratio (29.35) indicates premium valuation, which may pose a risk if clinical trial outcomes underperform expectations. However, the forward P/E of 111.11 signals market confidence in future earnings. Overall, ARWR may consolidate or decline in the near term but could rebound if upcoming clinical data are positive.